CELLECTIS - Export company showcase @ B2B French Export Directory

CELLECTIS is the world leader in applying the technology of Meganuclease Recombination Systems to in vivo genome engineering and genome surgery. The company is focused on the research and development of custom-Meganuclease Recombination Systems for in vivo DNA interventions and also provides new tools for rational genome engineering and targeted recombination in living cells. CELLECTIS develops recombination systems based on a novel class of genetic scissors: the Meganucleases. The technological breakthrough is the Meganuclease Recombination Systems (MRS) based on the Homologous Recombination and the Meganucleases. Cellectis' technology allow to perform precise modifications on chromosomes such as deletions, insertions or substitutions of genomic sequences. We design the meganuclease to target sequences of interest in the genome in vivo or ex vivo. CELLECTIS products are patented proprietary technologies. Applications of Meganuclease Recombination Systems (MRS)cover human genome therapy (somatic, stem cells and anti-viral), animal models, protein production and bioprocessed molecules or genetic improvement of plant or animal species.

Legal Name	CELLECTIS
Director Name	POLICARD Christian
French Legal Category	Limited liability company with board of directors
Registered capital (in Euros)	459 746
Year company founded	1/4/2000
Etablishment legal status	Limited liability company with board of directors
% Turnover from export	+70%
Related activities	Health, pharmacy, life sciences Biotechnology Services Services, others (R&D, postal services, etc.)

> French-Business-Home > Company : CELLECTIS